Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
2.
Klin Padiatr ; 223(4): 209-13, 2011 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-21509704

RESUMEN

BACKGROUND: Mycoplasma pneumoniae is an important aetiological agent of encephalitis in children, with encephalitis being the most frequent paediatric extrapulmonary manifestation of M. pneumoniae infections. Evidence of M. pneumoniae involvement in childhood encephalitis is difficult to obtain, because M. pneumoniae is seldom detected in the cerebrospinal fluid and the clinical picture shows gradual onset. Therefore, we present a small case-study as a paradigm of M. pneumoniae-associated encephalitis in childhood and illustrate the importance of this entity based on a review of previously published cases. PATIENTS: We describe neurological signs and symptoms of 2 patients with M. pneumoniae-associated encephalitis in childhood. Respiratory symptoms with fever occurred in both children. They were seropositive for M. pneumoniae, but did not have the organism detected by PCR from cerebrospinal fluid. No long-term neurologic sequelae occurred. CONCLUSION: M. pneumoniae has to be considered as a responsible pathogen of encephalitis in children, even if respiratory symptoms do not occur. Due to the seldom detection of M. pneumoniae in cerebrospinal fluid, evidence of m. pneumoniae involvement in childhood encephalitis is difficult to obtain.Faced with a neurological disease with no organism detected in CNS in the majority of cases assumes that M. pneumoniae-associated encephalitis is most likely a paradigm for an autoimmune disease with uniform pathogenesis mediated by an immunologic response to an antecedent antigenic stimulus from M. pneumoniae. It is important to relate this organism to this relatively common and potentially devastating clinical syndrome.


Asunto(s)
Encefalitis/diagnóstico , Infecciones por Mycoplasma/diagnóstico , Mycoplasma pneumoniae , Neumonía por Mycoplasma/diagnóstico , Antibacterianos/uso terapéutico , Líquido Cefalorraquídeo/microbiología , Niño , Preescolar , Diagnóstico Diferencial , Quimioterapia Combinada , Encefalitis/tratamiento farmacológico , Reacciones Falso Negativas , Femenino , Humanos , Masculino , Infecciones por Mycoplasma/tratamiento farmacológico , Examen Neurológico , Neumonía por Mycoplasma/tratamiento farmacológico , Reacción en Cadena de la Polimerasa
4.
Praxis (Bern 1994) ; 99(1): 61-5, 2010 Jan 06.
Artículo en Alemán | MEDLINE | ID: mdl-20052641

RESUMEN

Ramsay Hunt syndrome (RHS) is defined as a peripheral facial nerve palsy accompanied by an erythematous vesicular rash on the ear (zoster oticus) and hard palate. It is known that varicella zoster virus (VZV) causes RHS. History and neurological examination remain the mainstay of diagnosis. Prednisolone and acyclovir/valacyclovir is helpful in RHS when given within three days of onset. We report on a 14-year-old boy who had RHS accompanied by meningitis. Polymerase chain reaction identified VZV in exudates from the geniculate zone of the ear, the hard palate and in the CSF.


Asunto(s)
Parálisis de Bell/diagnóstico , Herpes Zóster Ótico/diagnóstico , Paladar Duro , Adolescente , Antiinflamatorios/uso terapéutico , Parálisis de Bell/tratamiento farmacológico , Diagnóstico Diferencial , Estudios de Seguimiento , Herpes Zóster Ótico/tratamiento farmacológico , Humanos , Masculino , Prednisolona/uso terapéutico
7.
Schweiz Med Wochenschr ; 130(43): 1581-9, 2000 Oct 28.
Artículo en Alemán | MEDLINE | ID: mdl-11100511

RESUMEN

UNLABELLED: Renal transplantation is the treatment of choice for paediatric patients with end-stage renal failure. Living donor transplantation (LDT) has become an important therapeutic option due to the shortage of cadaver donors and increasingly long waiting times. METHODS: Between 1992 and 1999, a total of 48 paediatric and adolescent patients underwent renal transplantation in Zurich. Of these, 21 patients (44%) received a kidney from a living related donor. 11 patients had been dialysed before LDT over a period of 0.2-5.7 years (median 0.6), and 10 were transplanted preemptively. Triple immunosuppression consisted of cyclosporine A, azathioprine or mycophenolate mofetil (MMF; since 1998), and prednisone. The observation period was 0.5-7.3 years (median 2). RESULTS: Recipients were 2-18 (median 10.5) years old at transplantation. One third had either a congenital malformation, an inherited disease, or an acquired disorder. One patient died of an associated cardiac disease at 4 months with functioning graft, and one functional graft loss occurred after 2.8 years. 9 patients were switched from cyclosporine to tacrolimus, 7 for biopsy-proven rejection and 2 for cosmetic reasons (hypertrichosis). No antibody preparations were used. Median glomerular filtration rate (51Cr-EDTA), measured after one year in 11 donor/recipients, was 64 (55-95) and 54 (32-82) ml/min/1.73 m2, respectively. The most recent estimated renal function (Schwartz formula) of 19 functioning grafts was 37-79 ml/min/1.73 m2 (median 63). Median body height of 16 patients with no associated extrarenal disease was -0.9 SDS (standard deviation score); the remaining 3--with serious extra-renal disease--were considerably growth retarded. Main complications were reversible rejection episodes in 19 (90%), arterial hypertension (16), CMV disease (2) and asymptomatic CMV infection (3), pyelonephritis (3), and recurrence of the primary renal disease, seizures, diabetes mellitus and non-compliance (one each). Actuarial patient and graft survival (Kaplan-Meier) after 3 years was 95 and 83% respectively. This was not statistically different from the cadaveric donor group (n = 27) with 100 and 80% survival respectively. Overall rehabilitation was excellent. The donors were 12 mothers, 8 fathers and one grandmother aged 31 to 50 (median 39) years; none of them experienced serious postoperative problems. CONCLUSIONS: The paediatric transplantation programme would no longer be feasible in Switzerland without LDT. The results are very encouraging; preemptive transplantation makes it possible to avoid dialysis in half of the patients. The risk for the donor is small, and careful evaluation without putting pressure on the family is essential.


Asunto(s)
Supervivencia de Injerto , Trasplante de Riñón/estadística & datos numéricos , Donadores Vivos , Adolescente , Adulto , Cadáver , Niño , Preescolar , Femenino , Estudios de Seguimiento , Tasa de Filtración Glomerular , Humanos , Lactante , Fallo Renal Crónico/cirugía , Trasplante de Riñón/mortalidad , Trasplante de Riñón/fisiología , Donadores Vivos/estadística & datos numéricos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Tasa de Supervivencia , Suiza , Donantes de Tejidos/provisión & distribución
8.
Pediatr Nephrol ; 14(8-9): 713-6, 2000 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-10955913

RESUMEN

We report two pediatric patients with end-stage renal failure who developed heparin-induced thrombocytopenia type II (HIT II) on hemodialysis (HD). Both developed acute respiratory distress and chest pain within 30 min of initiating the 5th HD session. The platelets dropped during HD from 168 to 38x10(9)/l and from 248 to 109x10(9)/l, respectively. Marked clots were observed in the dialyzers. Substitution of heparin with the low molecular weight heparin dalteparin had no effect. Switching from anticoagulation to the heparinoid danaparoid resulted in immediate disappearance of all adverse effects, and further long-term HD was uneventful. HIT II was diagnosed clinically; heparin-induced platelet activation test (HIPA) and serum IgG, IgA, and IgM to heparin-platelet factor 4 complexes (HPF4) were both negative. We conclude that HIT II may occur in children on HD. HIT II is essentially a clinical diagnosis, as HIPA and antibodies to HPF4 are not always positive. Once HIT II is suspected, heparin (and low-molecular-weight heparins) should be stopped immediately. Long-term anticoagulation with danaparoid is a valuable option for patients on HD.


Asunto(s)
Anticoagulantes/uso terapéutico , Sulfatos de Condroitina/uso terapéutico , Dermatán Sulfato/uso terapéutico , Heparina/efectos adversos , Heparitina Sulfato/uso terapéutico , Fallo Renal Crónico/terapia , Diálisis Renal/efectos adversos , Trombocitopenia/inducido químicamente , Adolescente , Anticoagulantes/efectos adversos , Niño , Dalteparina/efectos adversos , Combinación de Medicamentos , Humanos , Masculino , Recuento de Plaquetas
9.
Praxis (Bern 1994) ; 87(47): 1593-9, 1998 Nov 19.
Artículo en Alemán | MEDLINE | ID: mdl-9865130

RESUMEN

Since 1985, 20 children have been followed with early onset of chronic renal failure (plasma creatinine > 120 mumol/l in first year of life). So far, 10 and 7 patients underwent peritoneal dialysis and renal transplantation, respectively. The aim of this study was to assess the overall costs. The recorded costs comprised both the direct costs of dialysis and transplantation, and the costs of all medical and psychosocial measures. The annual median costs of conservative treatment, peritoneal dialysis, the year of transplantation, and follow-up after transplantation amounted to 30,000, 93,000, 130,000 and 28,000 Swiss francs, respectively. The youngest patients caused the highest expenses. The active treatment permitted not only survival, but--in most patients--also a normal cognitive and psychosocial development.


Asunto(s)
Fallo Renal Crónico/economía , Adolescente , Niño , Preescolar , Costos y Análisis de Costo , Femenino , Estudios de Seguimiento , Humanos , Lactante , Recién Nacido , Fallo Renal Crónico/rehabilitación , Trasplante de Riñón/economía , Masculino , Diálisis Peritoneal/economía , Suiza
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA